Time to first (a) moderate/severe exacerbation, (b) exacerbation... | Download Scientific Diagram
PPT – TOwards a Revolution in COPD Health the TORCH trial PowerPoint presentation | free to view - id: 1f8e5c-ZDc1Z
Determinants of exacerbation risk in patients with COPD in the TIOSPIR | COPD
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD | NEJM
ACCEPT 2·0: Recalibrating and externally validating the Acute COPD exacerbation prediction tool (ACCEPT) - eClinicalMedicine
Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial | Respiratory Research | Full Text
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
Cardiovascular events in patients with COPD: TORCH Study results | Thorax
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease | NEJM
Inhaled corticosteroids in COPD and the risk for coronary heart disease: a nationwide cohort study | Scientific Reports
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study - The Lancet Respiratory Medicine
The TORCH (TOwards a Revolution in COPD Health) survival study protocol | European Respiratory Society
Inhaled therapy reduces COPD mortality | European Respiratory Society
Cureus | A Review of Clinical Trials That Contributed to Chronic Obstructive Pulmonary Disease Treatment Protocols
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease | NEJM
Change in rate of decline in Fev 1 in UPLIFT ® and TOrCH, including... | Download Scientific Diagram
β-Blockers in COPD - CHEST
State-of-the-Art Overview of COPD and its Management
Inhaled corticosteroids in COPD: quantifying risks and benefits | Thorax
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease | NEJM
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results | European Respiratory Society
COPD: which medicines for which patients? | Addressing Unmet Medical Needs in COPD Management
PREVENTING COPD EXACERBATIONS - ppt download
Long-term outcomes following first short-term clinically important deterioration in COPD | Respiratory Research | Full Text
